We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Novel Perspectives in Pseudomyxoma Peritonei Treatment.
- Authors
Sommariva, Antonio; Tonello, Marco; Rigotto, Giulia; Lazzari, Nayana; Pilati, Pierluigi; Calabrò, Maria Luisa
- Abstract
Simple Summary: Pseudomyxoma Peritonei (PMP) represents a rare entity which greatly benefits from Cytoreductive Surgery (CRS) associated with Hyperthermic Intraperitoneal Chemotherapy (HIPEC). In fact, CRS-HIPEC represents the treatment with potential chances of cure and long-term disease control of patients affected by PMP. This therapeutic strategy should be performed in referral centers, where a consolidated know-how of this locoregional treatment and a multidisciplinary approach are available. CRS-HIPEC provides excellent results for PMP patients in terms of postoperative outcome, overall and disease-free survival, and quality of life. However, in patients with an extensive or recurrent disease, few therapeutic opportunities are available. This review is focused on the most recent clinical evidence and provides a better understanding of the molecular prognostic factors and potential therapeutic targets in this rare malignancy. Pseudomyxoma Peritonei (PMP) is an anatomo-clinical condition characterized by the implantation of neoplastic cells on peritoneal surfaces with the production of a large amount of mucin. The rarity of the disease precludes the evaluation of treatment strategies within randomized controlled trials. Cytoreductive Surgery (CRS) combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) has proven to be the only therapeutic option with potential chances of cure and long-term disease control. The present review discusses the epidemiology, pathogenesis, clinical presentation and treatment of PMP, focusing on the molecular factors involved in tumor progression and mucin production that could be used, in the upcoming future, to improve patient selection for surgery and to expand the therapeutic armamentarium.
- Subjects
DISEASE progression; PROTEINS; OPERATIVE surgery; CANCER chemotherapy; PERITONEUM tumors
- Publication
Cancers, 2021, Vol 13, Issue 23, p5965
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers13235965